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and ER tolterodine patients remained on treatment until week 52, respectively. QALYs 
were higher with fesoterodine than tolterodine (0.762 vs. 0.760). In Spain, fesoterodine 
treatment had higher costs than (generic) ER tolterodine (€ 6 697 vs. € 6 597), resulting 
in a cost of € 15 600/QALY gained. In Finland, fesoterodine was cost-saving relative to 
(non-generic) ER tolterodine (€ 7 885 vs. € 8 024). Sensitivity analysis confirmed these 
findings were robust to the expected price decrease for generic ER tolterodine in 
Finland. In the PSA, fesoterodine was consistently the preferred therapy in Finland 
regardless of the value of a QALY and in Spain for QALY valuations greater than 
€ 15 000. ConClusions: Fesoterodine is cost-effective or cost-saving relative to ER 
tolterodine for the treatment of OAB with UUI in two European countries. Payers and 
prescribers should consider a broad scope of costs in order to make informed cost-
conscious choices of antimuscarinic treatment.
PUK20
Economic EvalUation of Pharmacological trEatmEnts for 
ovEractivE BladdEr
Posnett J.1, Walker A.1, Nazir J.2, Odeyemi I.A.O.3, Hakimi Z.4, Garnham A.3
1Heron Evidence Development, Ltd., London, UK, 2Astellas Pharma Europe Ltd., Chertsey, UK, 
3Astellas Pharma Europe Ltd., Chertsey, UK, 4Astellas Pharma Global Development, Leiden, The 
Netherlands
objeCtives: Overactive bladder (OAB) is a chronic condition which affects quality 
of life through the main symptoms of urinary urgency, urinary frequency, and uri-
nary incontinence. Treatments include behavioural therapy, antimuscarinics (AM), 
β 3-adrenoceptor agonsits (mirabegron), botulinum toxin (botox) and sacral nerve stimu-
lation (SNS). The aim of this analysis was to evaluate the costs and outcomes associated 
with different sequences of oral treatments (AM and mirabegron). Methods: A Markov 
model with monthly cycle length and a time horizon up to 3 years compared two dif-
ferent sequences of up to three lines of oral treatments. Patients who discontinue one 
oral medication may switch to another oral medication, or may discontinue treatment. 
Patients whose symptoms are not improved are considered for botox or SNS. Outcomes 
are measured by (a) number of patients with improved symptoms (< 2 incontinence 
episodes and < 8 micturitions per 24-hours); (b) patients with < 2 incontinence epi-
sodes per 24-hours; and (c) patients with < 8 micturitions per 24-hours. Results: 
Including a third-line oral medication before considering other treatment options 
improved all patient outcomes, irrespective of the particular drugs used. A three-line 
sequence including two generics (oxybutynin (1st line), and tolterodine ER (2nd line)), 
and one branded drug (solifenacin 5mg (3rd line)) resulted in inferior patient outcomes 
and higher cost compared with a sequence of branded drugs (mirabegron (1st line), 
solifenacin 5mg (2nd line), solifenacin 10mg (3rd line)): improved patients (70/1000 
vs. 92/1000); patients with < 2 incontinence episodes (181/1000 vs. 217/1000); patients 
with < 8 micturitions (248/1000 vs. 299/1000). Annual treatment costs were higher in 
the generic sequence (£2659 per patient vs. £2479). ConClusions: Low-cost generic 
treatments are not necessarily more cost-effective than branded drugs. The main rea-
son is that a better efficacy and tolerability balance improves symptoms and quality of 
life, leading to better persistence and lower overall treatment costs.
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objeCtives: Mirabegron is a first-in-class beta-3 adrenoceptor agonist for the treat-
ment of overactive bladder (OAB) that demonstrated superior efficacy compared to 
placebo in OAB. The cost-effectiveness of mirabegron 50 mg (MGN) was assessed in 
comparison with tolterodine ER 4 mg (TOL) in the UK. Methods: A Markov model 
was developed to simulate the therapeutic management, the changes in symptoms 
(micturitions and incontinence), and complications in OAB patients. The model was 
used to predict costs and QALYs over 5 years in cohorts initially treated with MGN 
or TOL, followed by antimuscarinics in case of lack of efficacy or adverse events. 
Transition probabilities and EQ-5D utilities were obtained from regression models, 
estimated from a P3 randomized controlled trial of mirabegron. Costs were evalu-
ated from the UK National Health Service (NHS) perspective and included drug 
acquisition, physician visits, pads and botulinum toxin injections. Subgroup analy-
ses were performed for previously treated, treatment naïve, incontinent, female and 
elderly patients. Results: The MGN strategy was more expensive compared to 
TOL, with a difference of £37.88 per patient, and produced more QALYs (+0.009 per 
patient). The incremental cost-effectiveness ratio (ICER) was estimated at £4,386/
QALY gained. Results of one-way sensitivity analyses showed that in all scenarios, 
except one (the transition probabilities between symptom levels of micturition for 
mirabegron), MGN remained cost-effective or was dominant compared to TOL. Key 
cost-effectiveness drivers included parameters related to efficacy and treatment 
discontinuation. Based on the probabilistic sensitivity analysis, the probability of 
MGN being cost-effective against TOL was 89.4% at a threshold of £20,000 per QALY 
gained. ICERs in subgroups ranged from £3,091 (female subgroup) to £5,736 (elderly 
subgroup). ConClusions: Treatment with mirabegron 50 mg appears to be a cost-
effective strategy compared with tolterodine ER 4 mg for the general OAB population 
and the specified subgroups, from a UK NHS perspective.
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with comparable costs. Therefore, an incremental cost-effectiveness ratio was cal-
culated. Due to the possibility of declining adherence to drug therapy over time, 
pelvic floor physical therapy can be considered as the first line treatment for UUI.
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objeCtives: Hypertension is a chronic medical condition and an important risk 
factor in several fatal and debilitating diseases. NICE estimates the cost of pharma-
cologic intervention in the UK for hypertension at £409.8 million. Resistant hyper-
tension arises when blood pressure remains uncontrolled despite antihypertensive 
treatment. Renal denervation is a new procedure aimed at reducing blood pressure 
in resistant hypertension patients by decreasing efferent sympathetic signalling to 
the kidneys. The objective of this research was to review the evidence on the cost of 
renal denervation and to provide a costing model for the procedure. Methods: A 
targeted review of costing data was performed and information gathered from renal 
denervation experts to establish relevant procedure costs. Once specific health care 
resource use (HRU) and equipment costs were identified, an Excel™ costing model 
was constructed. A further search of NHS costing documents, academic literature, 
and expert consultation provided GBP figures for each cost and identified those that 
were time dependent (e.g. hourly staff costs). Results: The required in-patient 
HRU was identified as staff costs per hour including surgeon costs, nurse costs, 
technician costs and anaesthesiologist costs, all of which vary with procedure time 
depending on the device used (ranging from 20-60 minutes). Catheter lab overhead 
costs per hour and recovery costs (bed days) were also identified. Total HRU costs 
vary between £923.02 and £991.62 (for 20 and 60 minute procedure times respec-
tively). An additional in-hospital recovery day adds £680. Equipment costs were for 
12 items including from syringes to catheters to valves, totaling £281.70 plus the 
cost of the renal denervation therapy device. ConClusions: It is essential the 
cost of the procedure is estimated to fully inform payers and health care providers. 
HRU costs are dependent on procedure time and length of recovery in hospital, thus 
devices that reduce these factors are best for cost savings.
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objeCtives: Despite significant improvements in survival and quality of life (QoL) 
of liver transplant (LTx) recipients, patients remain at risk from complications 
related to disease recurrence and long-term use of immunosuppressant (IS). The 
objective was to assess cost, survival, and QoL outcomes of LTx recipients and 
the impact of renal dysfunction on LTx outcomes. Methods: A de novo cohort 
Markov model was developed to predict long-term outcomes post LTx along two 
independent pathways: 1) liver-related (acute rejection, hepatocellular carcinoma, 
hepatitis C (HCV) recurrence, graft loss), 2) kidney-related (chronic kidney disease, 
dialysis, renal transplantation) and death. All patients, stratified by liver diagno-
sis, entered the model at time of LTx and followed both pathways, allowing for 
multiple combinations of liver and kidney health states. Costs and utilities were 
assigned to each health renal and liver state. Renal complications costs and utility 
decrements were added to those accrued in the liver pathway. The lifetime model 
used an annual cycle length except for the 1st year post LTx (quarterly). Choice of 
immunosuppressant strategy could impact the risk of acute rejection, change in 
renal function and HCV fibrosis progression. A 3% discount rate was applied to 
costs and outcomes. Results: On average, life expectancy post LTx was 13.3 years 
with 10.2 QALYs. Lifetime cost of managing post LTx recipients was USD 550,000 
(excluding LTx procedure): > 50% was related to IS regimen, monitoring and adverse 
events; around 40% to renal complications and 2-7% to liver complications. Patients 
developing renal dysfunction lost 5.2 life-years and 1.5 QALYs. ConClusions: To 
our knowledge, this is the first Markov model simulating lifetime costs and out-
comes post-LTx and the impact of change in renal function on patient survival. A 
health care intervention that could improve or maintain renal function would have 
significant impact on survival and costs.
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objeCtives: To assess the economic value of fesoterodine compared to tolterodine 
for the treatment of overactive bladder (OAB) with urgency urinary incontinence (UUI) 
in Spain and Finland. Methods: A decision-tree economic model estimated the 
52-week costs and quality-adjusted life years (QALYs) of OAB/UUI patients initiating 
treatment with fesoterodine 4mg/day or extended-release (ER) tolterodine. Treatment 
response (UUI < 1 episode/day) and persistence were evaluated at weeks 4, 12, and 24. 
Titration from fesoterodine 4mg/day to 8mg/day was permitted at week 4. At week 
12, non-responders discontinued treatment permanently. Efficacy, discontinuation, 
and utility data were derived from four clinical trials of fesoterodine. OAB-related 
costs including physician visits, laboratory tests, incontinence pads, and comorbidi-
ties (fracture, skin infection, urinary tract infections, depression, and nursing home) 
were also included. The perspective was that of the National Health Systems (2012€ ). 
Uncertainty surrounding the model parameters was assessed by univariate and prob-
abilistic sensitivity analysis (PSA). Results: A total of 19.5% and 18.0% of fesoterodine 
